Medipharm Financial Statements From 2010 to 2025

LABS Stock  CAD 0.07  0.01  6.25%   
Medipharm Labs financial statements provide useful quarterly and yearly information to potential Medipharm Labs Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Medipharm Labs financial statements helps investors assess Medipharm Labs' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Medipharm Labs' valuation are summarized below:
Gross Profit
14.3 M
Profit Margin
(0.30)
Market Capitalization
30.8 M
Enterprise Value Revenue
0.4711
Revenue
39 M
We have found one hundred twenty available fundamental ratios for Medipharm Labs, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Medipharm Labs' last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 4th of March 2025, Market Cap is likely to drop to about 25.8 M. In addition to that, Enterprise Value is likely to drop to about 8.7 M

Medipharm Labs Total Revenue

39.66 Million

Check Medipharm Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medipharm Labs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 398.8 K or Selling General Administrative of 14.7 M, as well as many indicators such as Price To Sales Ratio of 0.78, Dividend Yield of 0.0 or PTB Ratio of 0.49. Medipharm financial statements analysis is a perfect complement when working with Medipharm Labs Valuation or Volatility modules.
  
This module can also supplement various Medipharm Labs Technical models . Check out the analysis of Medipharm Labs Correlation against competitors.

Medipharm Labs Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets75.9 M73.5 M44 M
Slightly volatile
Short and Long Term Debt Total2.5 M2.6 M2.8 M
Slightly volatile
Other Current Liabilities4.6 M7.4 M2.9 M
Slightly volatile
Total Current Liabilities13.7 M12.5 M7.9 M
Slightly volatile
Total Stockholder Equity59.2 M61 M34.5 M
Slightly volatile
Net Tangible Assets59.3 M95.6 M40.4 M
Slightly volatile
Accounts Payable1.8 M1.9 M2.9 M
Slightly volatile
Cash19.7 M20.7 M11.6 M
Slightly volatile
Cash And Short Term Investments19.7 M20.7 M11.6 M
Slightly volatile
Common Stock Shares Outstanding438.7 M417.8 M132 M
Slightly volatile
Liabilities And Stockholders Equity75.9 M73.5 M44 M
Slightly volatile
Total Liabilities17.1 M12.6 M9.7 M
Slightly volatile
Total Current Assets52 M42.1 M29.6 M
Slightly volatile
Accumulated Other Comprehensive Income35.6 M33.9 M11.7 M
Slightly volatile
Short Term Debt2.7 M2.6 M1.6 M
Slightly volatile
Common Stock120.7 M230.3 M76.8 M
Slightly volatile
Property Plant And Equipment Net25.4 M29.1 M14.5 M
Slightly volatile
Non Current Assets Total27.7 M31.4 M15.7 M
Slightly volatile
Common Stock Total Equity167.2 M159.3 M62.9 M
Slightly volatile
Short Term Investments289.5 K304.8 K358.2 K
Slightly volatile
Other Current Assets2.5 M3.3 M1.6 M
Slightly volatile
Net Invested Capital73.3 M63.4 M37.9 M
Slightly volatile
Cash And Equivalents22.9 M27.8 M12.7 M
Slightly volatile
Net Working Capital44.1 M29.6 M22.3 M
Slightly volatile
Property Plant Equipment25 M20.8 M13.5 M
Slightly volatile
Current Deferred Revenue122.4 K128.8 K341.3 K
Slightly volatile
Net ReceivablesM5.3 M10.4 M
Pretty Stable
Capital Surpluse65.9 K74.2 K80.9 K
Slightly volatile
Inventory14.9 M8.9 M13.2 M
Pretty Stable
Property Plant And Equipment Gross43.5 M60.1 M28.3 M
Slightly volatile
Short and Long Term Debt2.8 M1.9 M4.4 M
Slightly volatile
Capital Stock154.7 M230.3 M77.1 M
Slightly volatile
Capital Lease Obligations329.8 K171 K725.4 K
Slightly volatile
Other Liabilities200.9 K211.5 K3.4 M
Slightly volatile
Intangible Assets1.2 M1.2 M378.5 K
Slightly volatile

Medipharm Labs Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.6 M2.9 M2.1 M
Slightly volatile
Selling General Administrative14.7 M24.9 M10.1 M
Slightly volatile
Selling And Marketing Expenses3.2 M3.6 M1.9 M
Slightly volatile
Other Operating Expenses57.2 M59.7 M33.4 M
Slightly volatile
Total Operating Expenses18.8 M26.5 M12.5 M
Slightly volatile
Interest Income917.7 K966 K1.1 M
Slightly volatile
Research Development178.7 K188.1 K523.4 K
Slightly volatile
Cost Of Revenue35 M26 M23.3 M
Slightly volatile
Reconciled Depreciation4.6 M2.9 M2.5 M
Slightly volatile

Medipharm Labs Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow17.5 M27.8 M10.8 M
Slightly volatile
Depreciation3.8 M2.9 M2.5 M
Slightly volatile
Capital Expenditures402.7 K423.9 K4.7 M
Very volatile
End Period Cash Flow20 M20.7 M11.7 M
Slightly volatile
Change To Netincome8.1 M16.2 M6.3 M
Slightly volatile
Stock Based Compensation3.2 M1.8 M2.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.780.8212.9032
Slightly volatile
PTB Ratio0.490.5116.2763
Slightly volatile
Days Sales Outstanding70.7574.47196
Slightly volatile
Stock Based Compensation To Revenue0.120.07050.1513
Slightly volatile
Capex To Depreciation0.20.229.2568
Slightly volatile
PB Ratio0.490.5116.2763
Slightly volatile
Inventory Turnover2.022.471.5593
Slightly volatile
Days Of Inventory On Hand225153376
Slightly volatile
Payables Turnover6.8911.54.767
Slightly volatile
Sales General And Administrative To Revenue0.50.590.5775
Slightly volatile
Research And Ddevelopement To Revenue0.00540.00570.0265
Very volatile
Capex To Revenue0.01560.01640.8401
Slightly volatile
Cash Per Share0.05490.05780.1246
Slightly volatile
Days Payables Outstanding31.2232.86281
Slightly volatile
Intangibles To Total Assets0.01530.01450.0043
Slightly volatile
Current Ratio3.083.044.4137
Slightly volatile
Receivables Turnover5.335.072.4558
Slightly volatile
Graham Number0.290.310.6466
Pretty Stable
Shareholders Equity Per Share0.120.130.2389
Pretty Stable
Debt To Equity0.04730.04980.283
Very volatile
Capex Per Share0.00140.00150.2484
Slightly volatile
Revenue Per Share0.09940.10.1942
Very volatile
Interest Debt Per Share0.0080.00840.0483
Very volatile
Debt To Assets0.03920.04130.2615
Very volatile
Operating Cycle437227581
Slightly volatile
Price Book Value Ratio0.490.5116.2763
Slightly volatile
Days Of Payables Outstanding31.2232.86281
Slightly volatile
Ebt Per Ebit1.090.841.0133
Slightly volatile
Company Equity Multiplier1.421.391.2935
Slightly volatile
Long Term Debt To Capitalization0.07060.110.0772
Slightly volatile
Total Debt To Capitalization0.04530.04770.1292
Pretty Stable
Debt Equity Ratio0.04730.04980.283
Very volatile
Quick Ratio2.462.213.9293
Slightly volatile
Net Income Per E B T0.70.880.9133
Slightly volatile
Cash Ratio2.271.93.3966
Slightly volatile
Cash Conversion Cycle311194294
Slightly volatile
Days Of Inventory Outstanding225153376
Slightly volatile
Days Of Sales Outstanding70.7574.47196
Slightly volatile
Price To Book Ratio0.490.5116.2763
Slightly volatile
Fixed Asset Turnover1.511.51.0664
Slightly volatile
Debt Ratio0.03920.04130.2615
Very volatile
Price Sales Ratio0.780.8212.9032
Slightly volatile
Asset Turnover0.320.470.3186
Slightly volatile
Price Fair Value0.490.5116.2763
Slightly volatile

Medipharm Labs Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap25.8 M27.2 M167 M
Slightly volatile

Medipharm Fundamental Market Drivers

Forward Price Earnings27.4725
Cash And Short Term Investments18 M

About Medipharm Labs Financial Statements

Medipharm Labs investors utilize fundamental indicators, such as revenue or net income, to predict how Medipharm Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue128.8 K122.4 K
Total Revenue38 M39.7 M
Cost Of Revenue26 M35 M
Stock Based Compensation To Revenue 0.07  0.12 
Sales General And Administrative To Revenue 0.59  0.50 
Research And Ddevelopement To Revenue 0.01  0.01 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.10  0.10 
Ebit Per Revenue(0.63)(0.67)

Pair Trading with Medipharm Labs

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medipharm Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medipharm Labs will appreciate offsetting losses from the drop in the long position's value.

Moving against Medipharm Stock

  0.31GOOG Alphabet CDRPairCorr
The ability to find closely correlated positions to Medipharm Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medipharm Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medipharm Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medipharm Labs Corp to buy it.
The correlation of Medipharm Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medipharm Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medipharm Labs Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medipharm Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Medipharm Stock

Medipharm Labs financial ratios help investors to determine whether Medipharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medipharm with respect to the benefits of owning Medipharm Labs security.